Nevro to Highlight Substantial Body of Clinical Evidence Supporting Expanded Applications and Unique Capabilities of HF10 Therapy at the 14th International Neuromodulation Society World Congress

[In The News]

SYDNEY, May 26, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the Company's HF10™ therapy for...

View the full article